Joshua Saipe, Chief Financial Officer
As US Fertility and Ovation Fertility’s Chief Financial Officer, Josh leverages his financial, strategic, operational, and leadership experience to lead all financial aspects of the Company, and to guide U.S Fertility and Ovation’s strategic and business activities. His areas of responsibility include reporting and analysis, accounting, corporate development and strategy, M&A, key growth and business initiatives, planning, capital allocation, capital structure and investments, treasury, revenue cycle, and tax. Josh joined US Fertility in November 2021, as Chief Strategy Officer and expanded his role in 2022 as CFO. Josh’s role expanded further to include CFO responsibilities for Ovation in May 2023. Josh brings over 22 years of healthcare, strategic leadership, operating, financial, investing, and transactional experience.
Josh joined US Fertility from Evernorth, where he was the head of the Evernorth Intelligence+ Data, Analytics, and Platform Solutions business, responsible for leadership, growth, and general management. Josh’s previous role at Express Scripts was leading corporate business development, where his experience included the development and execution of strategies and initiatives to complement, generate growth for, and strengthen the overall business, such as mergers and acquisitions, investments, and strategic and transactional partnerships across the enterprise and business units. Prior to joining Evernorth/Express Scripts, Josh had over 15 years of experience in healthcare private equity investing, healthcare executive, and investment banking roles. He previously worked with J.P. Morgan, RoundTable Healthcare Partners, Health Evolution Partners, and Freedom Innovations, and served as a Director on the Board of Prolacta Bioscience and Freedom Innovations.
Josh graduated from Tufts University with high honors, with a degree in International Relations.